Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

被引：5

作者：

Vinti, Luciana ^{[1
]}

Pagliara, Daria ^{[1
]}

Buffardi, Salvatore ^{[2
]}

Di Ruscio, Valentina ^{[1
]}

Stocchi, Francesca ^{[1
]}

Mariggio, Elena ^{[1
]}

Parasole, Rosanna ^{[2
]}

Di Matteo, Antonia ^{[2
]}

Petruzziello, Fara ^{[2
]}

Paganelli, Valeria ^{[1
]}

De Vito, Rita ^{[3
]}

Del Bufalo, Francesca ^{[1
]}

Strocchio, Luisa ^{[1
]}

Locatelli, Franco ^{[1
,4
]}

机构：

[1] IRCCS, Dept Paediat Haematol Oncol Cell & Gene Therapy, Bambino Gesu Childrens Hosp, Piazza S Onofrio 4, I-00165 Rome, Italy

[2] Santobono Pausilipon Childrens Hosp, Dept Paediat Haematol Oncol, Naples, Italy

[3] IRCCS, Dept Pathol, Bambino Gesu Childrens Hosp, Rome, Italy

[4] Univ Rome, Dept Pediat, Sapienza, Rome, Italy

来源：

PEDIATRIC BLOOD & CANCER | 2022年 / 69卷 / 04期

关键词：

brentuximab vedotin; Hodgkin lymphoma; immunotherapy; pediatric; refractory; relapse; STEM-CELL TRANSPLANTATION; PHASE-II; CHILDREN; THERAPY; MULTICENTER; GEMCITABINE; VINORELBINE; RECURRENT; EFFICACY; CANCER;

D O I：

10.1002/pbc.29557

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90-120 mg/m(2) on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.

引用

页数：9

共 50 条

[31] Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
Tien, Feng-Ming
Tsai, Cheng-Hong
Liu, Jia-Hau
Lin, Chien-Ting
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (10) : 1466 - 1470
[32] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
Massaro, Fulvio
Meuleman, Nathalie
Bron, Dominique
Maerevoet, Marie
BLOOD, 2020, 136
[33] A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma
Kaleka, Guneet
Moskoff, Benjamin
Zafar, Aneeqa
Esteghamat, Naseem S.
Abedi, Mehrdad
Socola, Francisco Andres
Hoeg, Rasmus T.
Tuscano, Joseph M.
BLOOD, 2024, 144 : 6318 - 6319
[34] BRENTUXIMAB VEDOTIN FOLLOWED BY BENDAMUSTINE SUPERCHARGE FOR REFRACTORY OR RELAPSED HODGKIN LYMPHOMA: MATURE RESULTS OF A MONOCENTRIC PROSPECTIVE TRIAL
Della Pepa, R.
Picardi, M.
Pugliese, N.
Giordano, C.
Leone, A.
Muriano, F.
Pane, F.
HAEMATOLOGICA, 2020, 105 : S101 - S102
[35] Brentuximab vedotin plus bendamustine as a bridge to transplantation in relapsed/refractory Hodgkin lymphoma in Hungary-realworld data
Li, Pinczes
Jona, A.
Illes, A.
Foldeak, D.
Piukovics, K.
Szomor, A.
Gopcsa, L.
Zs, Miltenyi
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S7 - S8
[36] Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
Massaro, Fulvio
Meuleman, Nathalie
Bron, Dominique
Vercruyssen, Marie
Maerevoet, Marie
CANCERS, 2022, 14 (04)
[37] A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
Cao, Zhi-Gang
Zhou, Hong-Wei
Peng, Chao-Jin
Liu, Mo
Du, Yu
Yang, Qing-Ming
CHINESE JOURNAL OF CANCER, 2013, 32 (09) : 520 - 523
[38] EXPERIENCE WITH BRENTUXIMAB VEDOTIN IN RELAPSED/ REFRACTORY HODGKIN LYMPHOMA IN THE PROVINCE OF CADIZ
Verdugo Cabeza De Vaca, Ma V.
Cuellar Garcia, C.
Romero Gonzalez, Ma dM
Fernandez Valle, Ma dC
Berruezo Salazar, Ma J.
Paz Coll, A.
Garzon Lopez, S.
HAEMATOLOGICA, 2015, 100 : 174 - 174
[39] Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
Angelopoulou, Maria K.
Vassilakopoulos, Theodoros P.
Batsis, Ioannis
Sakellari, Ioanna
Gkirkas, Konstantinos
Pappa, Vasiliki
Giannoulia, Panagiota
Apostolidis, Ioannis
Apostolopoulos, Christos
Roussou, Paraskevi
Panayiotidis, Panayiotis
Dimou, Maria
Kyrtsonis, Marie-Christine
Palassopoulou, Maria
Vassilopoulos, Georgios
Moschogiannis, Maria
Kalpadakis, Christina
Margaritis, Dimitrios
Spyridonidis, Alexander
Michalis, Eurydiki
Anargyrou, Konstantinos
Repousis, Panagiotis
Hatzimichael, Eleutheria
Bousiou, Zoi
Poulakidas, Elias
Grentzelias, Dimitrios
Harhalakis, Nikolaos
Pangalis, Gerassimos A.
Anagnostopoulos, Achilles
Tsirigotis, Panagiotis
HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 174 - 181
[40] A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
Zhi-Gang Cao
Hong-Wei Zhou
Chao-Jin Peng
Mo Liu
Yu Du
Qing-Ming Yang
ChineseJournalofCancer, 2013, 32 (09) : 520 - 523

← 1 2 3 4 5 →